A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.
Saved in:
| Title: | A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer. |
|---|---|
| Authors: | Knox JJ; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: Jennifer.knox@uhn.ca., McNamara MG; University of Manchester/The Christie NHS Foundation Trust, Manchester, UK., Bazin IS; N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Zubkov O; The State Institute 'Shalimov`s National Institute of Surgery and Transplantology' NAMS of Ukraine, Kyiv, Ukraine., Breder V; N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia., Bai LY; Division of Hematology and Oncology, China Medical University Hospital, and China Medical University, Taichung, Taiwan., Christie A; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., Goyal L; Massachusetts General Hospital, Boston, USA; Stanford University School of Medicine, Palo Alto, California, USA., Cosgrove DP; Division of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, USA., Springfeld C; Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany., Sjoquist KM; Cancer Care Centre, St George Hospital, Kogarah & NHMRC Clinical Trials Centre, University of Sydney, Australia., Park JO; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Verdaguer H; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Braconi C; University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK., Ross PJ; Guy's Cancer, Guy's & St Thomas' NHS Foundation Trust, London, UK., De Gramont A; Franco-British Institute, Levallois-Perret, France., Shroff RT; Division of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, USA., Zalcberg JR; Dept Medical Oncology, Alfred Health and School of Public Health Monash University, Melbourne Australia., Palmer DH; University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK., Smith JR; Adaptive Plus LLC, North Carolina, USA., Oelmann E; NuCana plc, Edinburgh, UK., Bruce T; NuCana plc, Edinburgh, UK., Valle JW; University of Manchester/The Christie NHS Foundation Trust, Manchester, UK; Cholangiocarcinoma Foundation, Utah, USA. |
| Source: | Journal of hepatology [J Hepatol] 2025 Aug; Vol. 83 (2), pp. 358-366. Date of Electronic Publication: 2025 Feb 18. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
